---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-010097"
form_type: "8-K"
ticker: "AZTR"
cik: "0001701478"
company_name: "Azitra, Inc."
filed_at: "2024-03-15T23:59:59+00:00"
generated_at: "2026-06-04T17:30:50.584220+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Azitra reports FY2023 net loss $11.3M, cash $1.8M; advances ATR-12 Phase 1b and ATR-04 IND

## Summary
- Net loss $11.3M vs $10.7M in 2022; service revenue from related party $0.7M.
- Cash and equivalents $1.8M at Dec 31, 2023, plus $4.4M net from Feb 2024 follow-on.
- ATR-12 for Netherton syndrome: Phase 1b trial enrolling ~12 patients; safety data in late 2024.
- ATR-04 for EGFRi-associated rash: IND submission mid-2024; first-in-human trial by late 2024/early 2025.
- Bayer joint development agreement progressing; expect license agreement with upfront payment.

## SEC filing metadata
- accession: 0001493152-24-010097
- form_type: 8-K
- ticker: AZTR
- cik: 0001701478
- company_name: Azitra, Inc.
- filed_at: 2024-03-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701478/000149315224010097/0001493152-24-010097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701478/000149315224010097/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-010097
- JSON: https://secwatch.observer/filing/0001493152-24-010097.json
- Plain text: https://secwatch.observer/filing/0001493152-24-010097.txt

## Key facts
- Earnings Releases
  Azitra, Inc. reported the full year ended December 31, 2023 results: revenue $0.7 million, net income $11.3 million.
  - Period: the full year ended December 31, 2023
  - Revenue: $0.7 million
  - Net income: $11.3 million
  - Result: reported results
  source text: ■ Execution of a licensing agreement with upfront payment Financial Results for the Year Ended December 31, 2023 ● Service Revenue – Related Party : The Company generated $0.7 million of service revenue during the year ended December 31, 2023, compared to $0.3 million for the comparable period in 2022. ● Research and Development (R&D) expenses : R&D
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701478/000149315224010097/0001493152-24-010097-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.